MedXY – Page 3 – Medxy AI

Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer: New Therapeutic Prospects

By MedXY 08/01/2025

A phase 2 study shows that bevacizumab and erlotinib combination therapy offers notable tumor responses and survival benefits in both hereditary and sporadic papillary renal-cell carcinoma, with manageable toxicity.

Clinical Updates Wellness & Lifestyle

Corynebacterium diphtheriae Outbreak among Migrants in Europe: Clinical, Epidemiologic, and Microbiologic Insights

By MedXY 08/01/2025

A multicountry outbreak of diphtheria among migrants in Europe raised concerns about cutaneous and respiratory disease, cross-border spread, and emerging antibiotic resistance. Genomic analysis revealed multiclonal transmission and resistance challenges for standard therapies.

Clinical Updates Wellness & Lifestyle

Zongertinib: A Promising Oral Targeted Therapy for Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer

By MedXY 08/01/2025

Zongertinib shows high response rates and manageable toxicity in HER2-mutant NSCLC after prior treatments, offering a new oral therapy option.

Clinical Updates Wellness & Lifestyle

Inebilizumab for Generalized Myasthenia Gravis: Results from a Phase 3 Randomized Trial

By MedXY 08/01/2025

A phase 3 trial shows inebilizumab, a CD19+ B-cell depleting antibody, improves function and reduces disease severity in generalized myasthenia gravis without increasing serious adverse events.

Clinical Updates Wellness & Lifestyle

Expanding Nonoperative Management in Mismatch Repair–Deficient Early-Stage Solid Tumors: Phase 2 Evidence for Neoadjuvant PD-1 Blockade

By MedXY 08/01/2025

Neoadjuvant PD-1 blockade with dostarlimab enabled organ preservation and high recurrence-free survival in early-stage mismatch repair–deficient (dMMR) solid tumors, extending nonoperative management beyond rectal cancer.

Clinical Updates Wellness & Lifestyle

Nab-Paclitaxel Plus Gemcitabine Outperforms mFOLFIRINOX and S-IROX as First-Line Therapy for Metastatic Pancreatic Cancer: Insights from the GENERATE (JCOG1611) Trial

By MedXY 08/01/2025

A large Japanese phase II/III trial shows nab-paclitaxel plus gemcitabine confers longer overall survival and better tolerability compared to mFOLFIRINOX and S-IROX in metastatic pancreatic cancer.

Clinical Updates Wellness & Lifestyle

Pirtobrutinib Demonstrates Superior Efficacy and Tolerability in cBTKi-Pretreated CLL/SLL: Insights from the BRUIN CLL-321 Phase III Trial

By MedXY 08/01/2025

Pirtobrutinib significantly improves progression-free survival and tolerability over standard regimens in covalent BTK inhibitor-pretreated CLL/SLL, offering a promising new option for this challenging population.

Clinical Updates Medical News

Lipoprotein(a) as an Independent Predictor of Peripheral Artery Disease and Carotid Stenosis: Insights from a Large UK Biobank Study

By MedXY 08/01/2025

A landmark UK Biobank study demonstrates that elevated lipoprotein(a) independently predicts both the onset and progression of peripheral artery disease and carotid stenosis, beyond traditional cardiovascular risk factors.

Clinical Updates Wellness & Lifestyle

Cilta-Cel CAR-T療法で再発・難治性多発性骨髄腫の長期予後：患者の3分の1が5年以上の寛解を達成

By MedXY 08/01/2025

最近のJ Clin Oncol研究では、cilta-cel治療を受けたRRMM患者の約33%が5年以上の無増悪生存を達成し、持続的な反応と有望なバイオマーカーが示されました。

$Long-Term Outcomes of Cilta-Cel CAR-T Therapy in Relapsed/Refractory Multiple Myeloma: Five-Year Remission Achieved in One-Third of Patients$

Clinical Updates Medical News

Long-Term Outcomes of Cilta-Cel CAR-T Therapy in Relapsed/Refractory Multiple Myeloma: Five-Year Remission Achieved in One-Third of Patients

By MedXY 08/01/2025

A recent J Clin Oncol study shows that nearly 33% of RRMM patients treated with cilta-cel achieved ≥5 years of progression-free survival, highlighting durable responses and promising biomarkers.